US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Cadrenal Therapeutics Inc (CVKD)
Cadrenal Therapeutics Inc (CVKD) ニュース

CVKD

Cadrenal Therapeutics (CVKD)

Cadrenal Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CVKD

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/13	05 : 10	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/06/12	06 : 27	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/06/12	06 : 25	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/06/03	22 : 00	PR Newswire (US)	Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/05/30	06 : 27	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/05/23	22 : 00	PR Newswire (US)	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/05/09	22 : 00	PR Newswire (US)	Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/05/09	19 : 23	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/04/12	05 : 30	PR Newswire (US)	Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/04/09	22 : 00	PR Newswire (US)	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/03/11	22 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/03/11	22 : 00	PR Newswire (US)	Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/03/06	07 : 24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/02/26	23 : 00	PR Newswire (US)	Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/02/15	22 : 00	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/02/13	06 : 49	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/02/08	23 : 00	PR Newswire (US)	Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/01/31	23 : 00	PR Newswire (US)	Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/01/24	23 : 00	PR Newswire (US)	Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/01/04	23 : 00	PR Newswire (US)	Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/12/19	23 : 00	PR Newswire (US)	Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/12/12	23 : 00	PR Newswire (US)	Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/12/01	06 : 15	PR Newswire (US)	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/11/09	23 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/11/09	23 : 00	PR Newswire (US)	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/11/09	22 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/10/24	06 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/10/10	05 : 15	PR Newswire (US)	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/09/09	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/09/05	21 : 00	PR Newswire (US)	Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress	NASDAQ:CVKD	Cadrenal Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:CVKD

1 2 3 次へ >>

Intesa Sanpaolo

Franklin Resources

Vontobel Financial Produ...

Brookfield Infrastructur...

Adb Fx 40% Aug25 Try

Mitsu Hc Cap.26

Hsbc Msci Japan Etf

BNP Paribas Issuance

BPCE 3.1% 17feb2027

Grit Investment

NLBNPIT20FX2 20240621 85

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約